[The adjuvant chemotherapy of breast cancer].
A clinical trial undertaken at Surgical Department No. I of the Institute included the data on 569 cases of stage I-III breast cancer treated in 1985-1989. Adjuvant CMF or TMF chemotherapy failed to improved 5-year survival (chemotherapy 2--285.2%, no chemotherapy--84.8%) in patients with stage I-IIa (TO-2NOMO) disease. Adjuvant treatment with adrioblastin proved superior over CMF and TMF in terms of 5-year overall survival in patients with stage III (T3NO-IMO; TO-3N2MO) cancer (71.0 and 55.0%, respectively).
Semiglazov
V F
VF
Golubeva
O M
OM
Bavli
Ia L
IaL
Ivanova
O A
OA
Topuzov
E E
EE
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D015409:Mastectomy, Radical; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D011300:Preoperative Care; D012426:Russia / Q000453:epidemiology; D013852:Thiotepa / Q000008:administration & dosage; D013997:Time Factors
D003520:Cyclophosphamide; D013852:Thiotepa; D005472:Fluorouracil; D008727:Methotrexate
Ad''iuvantnaia khimioterapiiaraka molochnoĭ zhelezy.